SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a major talking point following its recent earnings report, which, despite beating on revenue and EPS, presented cautious forward guidance and a decision to pause share buybacks. This has ignited community debate, with many investors split between seeing a massive 'buy the dip' opportunity and expressing concern over slowing growth and the financial implications of a potential Warner Bros. Discovery acquisition. The discussion reflects a mixed outlook on whether strategic shifts will accelerate long-term value or introduce short-term headwinds.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to recent positive Phase 1 clinical trial data for its eczema treatment, soquelitinib, which demonstrated strong efficacy and a favorable safety profile, initially fueling a significant surge in interest. This positive momentum is now tempered by a proposed $150 million public offering, sparking a community debate between those who see it as a strategic capital raise for a potentially breakthrough oral therapy and those concerned about dilution for an early-stage drug.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending after CEO Ryan Cohen and another board member significantly increased their stakes in the company through recent share purchases. This insider buying has ignited a strong bullish sentiment among investors, who are actively discussing the potential for a short squeeze and viewing the moves as a vote of confidence. The stock's resilience amidst broader market volatility further fuels community speculation about future catalysts.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares ETF ($GLD) is trending strongly as escalating geopolitical tensions, particularly surrounding U.S.-Europe tariff threats over Greenland, drive a significant risk-off sentiment across markets. The community is actively discussing gold's role as a premier safe haven, pushing prices to new highs amidst global instability and concerns over economic and financial system shifts.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is experiencing a significant downturn, with many in the community attributing the "brutal day" to broader geopolitical tensions and proposed tariffs. Traders are hotly debating whether the stock's historically oversold RSI levels present a "buy the dip" opportunity ahead of its upcoming earnings report or if further declines are imminent due to perceived stagnation in AI innovation.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is experiencing significant volatility as former President Trump's strong stance on Greenland and related tariff threats generate global market uncertainty, prompting a shift away from U.S. assets. The community is split, with many anticipating a rapid rebound for tech stocks while others warn of a deeper correction driven by these geopolitical tensions and broader concerns about AI's market impact.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

Top Wealth Group Holding Ltd. is actively discussed following its announcement to acquire a wine authentication and trading business, a strategic move to diversify into luxury products. This development, however, coincides with a public offering of units, leading to significant price fluctuations. Community sentiment is divided between those anticipating a strong rally due to the news and low float, and others cautioning against a potential "Chinese pump and dump" given the offering and historical volatility.

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm, through its subsidiary, develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel C. Blackman in November 2018 and is headquartered in Brisbane, CA.

Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals is trending following robust preliminary 2025 Ojemda product revenue and optimistic 2026 guidance, alongside the recently completed acquisition of Mersana Therapeutics. The community is actively discussing significant options activity and renewed buyout speculation, as analysts upgrade ratings and view the Mersana deal as strengthening the company's pipeline and commercial prospects.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Advanced Micro Devices is drawing significant attention following a long-term data center leasing agreement with Riot Platforms, seen as a strategic move to secure direct AI infrastructure. This development, combined with strong analyst conviction in AMD's growing AI market share and its impressive resilience during broader market weakness, is fueling active community discussion about its promising long-term trajectory.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels Inc. is rapidly gaining attention following its strategic acquisition of Australian Strategic Materials and positive developments in expanding its rare earth processing capabilities. Investors are actively discussing the company's growing significance in securing America's critical mineral and uranium supply chains amidst increasing demand from AI and clean energy sectors, positioning UUUU as a cornerstone for national energy independence.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Results?

JNJ heads into Q4 earnings with strong pharma and MedTech momentum, offset by Stelara biosimilar pressure and China-related headwinds.

Teva Pharmaceutical Industries Ltd. $TEVA Stock Holdings Lifted by Harel Insurance Investments & Financial Services Ltd.

Harel Insurance Investments & Financial Services Ltd. lifted its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 12.9% in the 3rd quarter, according to the company in its...

Wall Street Zen Downgrades Teva Pharmaceutical Industries (NYSE:TEVA) to Buy

Wall Street Zen downgraded shares of Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a research note on Sunday...

ANIP vs. TEVA: Which Drug Stock Is the Better Buy Right Now?

ANI Pharmaceuticals' rare disease growth, led by surging Cortrophin Gel sales, is outpacing Teva's slower sales momentum in this head-to-head stock comparison.

Teva Pharmaceutical Industries Ltd. (TEVA) is a Top-Ranked Momentum Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Commonwealth Equity Services LLC Acquires 122,701 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Commonwealth Equity Services LLC raised its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 75.3% during the third quarter, according to its most recent filing with the...

Teva Pharmaceutical Industries (NYSE:TEVA) Reaches New 52-Week High - Time to Buy?

Teva Pharmaceutical Industries (NYSE:TEVA) Sets New 52-Week High - Here's What Happened...

TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug

Teva strikes a $500M funding deal with Royalty Pharma for the speedy development of its vitiligo candidate, TEV-'408, while keeping global commercial control.

Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

<ul class="summary-bullets"><li>TEV-408 is an antibody designed to block IL-15, a protein that plays a major role in driving immune-related diseases.</li><li>Teva expects 2025 revenues in the lower end of the $16.8–$17.0 billion range</li><li>TEVA stock is on track to open at its highest levels since July 2017.</li></ul>Shares of Teva Pharmaceuticals Industries (TEVA) rose more than 6% in premarket trading on Monday, after the company announced a funding agreement with Royalty Pharma (RPRX) of up to $500 million to advance Teva’s anti-IL-15 antibody, TEV-‘408, across its clinical programs.TEV-408 is Teva’s experimental antibody designed to block IL-15, a protein that plays a major role in driving immune-related diseases.<a href="https://stocktwits.com/symbol/TEVA">TEVA stock</a> is on track to open at its highest levels since July 2017.<h2 class="st-heading-2">Terms Of The Agreement</h2>The initial funding includes $75 million to support a Phase 2b study in vitiligo, an autoimmune condition that causes the loss of skin pigmentation, resulting in white patches. Royalty Pharma holds an option to provide an additional $425 million to co-fund Phase 3 development based on Phase 2b results.Under the agreement, milestone payments and royalties on worldwide net sales would be payable to Royalty Pharma if TEV-‘408 is approved and launched.The TEV-‘408 therapy is currently in Phase 1b for vitiligo and Phase 2a for celiac disease and has received Fast Track designation from the U.S. Food and Drug Administration (FDA). By blocking IL-15, TEV-‘408 aims to reduce immune-mediated destruction of melanocytes in vitiligo and intestinal inflammation in celiac disease.“This agreement with Royalty Pharma enables us to advance our science more efficiently and accelerate our pipeline to deliver meaningful solutions for patients worldwide. Vitiligo represents a significant unmet need, with only one approved topical treatment currently available and no systemic options. We are dedicated to driving scientific progress that brings new, effective therapies to people living with chronic autoimmune diseases,” said Richard Francis, Teva’s President and CEO.Teva expects 2025 revenues in the lower end of the $16.8–$17.0 billion range, flat to slightly lower in 2026, low-single-digit growth in 2027, and at a mid-single-digit compound annual growth rate through 2030.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the pre-market gain, retail sentiment on Stocktwits for TEVA turned ‘bearish’ from ‘neutral’ a day earlier, amid ‘high’ message volumes.One user sees the stock climbing to $40. It is currently at $33.8.<stembedurl>https://stocktwits.com/OX50/message/641481558</stembedurl>Over the past year, TEVA shares have gained over 50%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-inbs-stock-surging-again-today/cmUaGlNR4EJ">INBS Stock Has Surged Over 330% So Far In January – But Retail Traders Are Warning Of A Pullback</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Teva Pharmaceutical Industries’ logo is displayed on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Why Is TEVA Stock Rising Pre-Market Today?

Teva announced a funding agreement with Royalty Pharma of up to $500 million to advance its anti-IL-15 antibody, TEV-‘408, across its clinical programs.

Equity

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Teva- Pharmaceutical Industries Ltd. - ADR

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

TEVA
Teva- Pharmaceutical Industries Ltd. - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TEVA News

TEVATeva- Pharmaceutical Industries Ltd. - ADR